VIVUS Inc. (NASDAQ:VVUS)
VIVUS Inc. (NASDAQ:VVUS) stock is bouncing off its 52-week lows days after the stock took a dive despite generally meeting analyst expectations in last week’s Q2 financial release. Since that release, VVUS stock has lost around $0.10 per share on heavy volume.
VIVUS, Inc. (NASDAQ:VVUS) reported a loss of (-$0.13) per share for Q2 2017. One year ago, for the same quarter, VIVUS reported a loss of (-$0.11). Revenues, compared to the same quarter one year ago, decreased 18.5% to $11.2 million.
VIVUS, Inc. (NASDAQ:VVUS) is a global biopharmaceutical firm, based in Campbell, CA, that develops and commercializes therapies to treat unmet medical needs. VIVUS sells Qsymia for the treatment of obesity in adult patients. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. In addition, VIVUS is developing Tacrolimus, which has completed Phase IIa studies for the treatment of pulmonary arterial hypertension.
Shares of VIVUS, Inc. (NASDAQ:VVUS) have lagged their benchmark. YTD, VVUS stock is down over 11% but the stock is relatively flat for the year. The 52-week high is $1.47 but the analyst’s consensus target price is $2.15. Interestingly, VVUS shares are currently trading at over a 50% discount to their reported cash/share figure of $2.19.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $VVUS and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.